

Health Professionals Follow-Up Study

Dear Colleague,

Thank you for your longstanding participation in the Health Professionals Follow-Up Study. As you know, we are studying the determinants of long-term survival from prostate cancer. Through this study, we are gaining valuable insight about how diet and other factors can improve prognosis. Please note that we have all of your original diagnosis information. The purpose of this mailing, as we do every couple of years, is to obtain new follow-up information regarding your prostate cancer. Even if nothing has changed, that information is still important to our study.

We would greatly appreciate it if you could complete the enclosed questionnaire regarding your prostate cancer and return it to us in the envelope provided. We realize this is a lengthy questionnaire; please fill out whatever you can. Your participation is completely voluntary, and if you do not wish to participate in this study on prostate cancer survival, you will still be a valuable member of the Health Professionals Follow-Up Study. By participating, you will be making a key contribution to our understanding of prostate cancer, which may ultimately lead to strategies geared at prevention or cure. Please do not hesitate to call me or Dr. Lorelei Mucci at 617-998-1067 if you have any questions about the study.


Sincerely Yours,

Walter C. Willett, M.D.

Walter Willett

Principal Investigator

Lorelei Mucci, ScD. Co-Principal Investigator



PLEASE USE AN ORDINARY NO. 2 PENCIL TO ANSWER ALL QUESTIONS.

Fill in the appropriate response circles completely, or write the requested information in the boxes provided. The form is designed to be read by optical-scanning equipment, so it is important that you make <u>NO STRAY MARKS</u> and keep any write-in responses within the spaces provided. Should you need to change a response, erase the incorrect mark completely. If you have comments, please write them on a separate piece of paper.

Please fill in the circles completely; do not mark this way: 🕜 🕱 🗅

31a. Mark all of the treatments you have had <u>since January 2022</u> and provide the dates as best as you can.

Treatment/medication since January 2022 only	Start date or procedure date	End date or	Currently doing/taking?
Procedures	Year	Year	
Radical prostatectomy		N/A	
2. Radiation to the pelvis (external beam,	0000		
proton beam, cyberknife, etc.)	2022		
3. O Brachytherapy/seeds		N/A	0
4. Cryosurgery/cryoablation		N/A	O
5. High intensity focused ultrasound (HIFU)		N/A	0

The research team has great respect for your continued study participation, and therefore would like to remind you of several important points, as is standard practice in research. We do so in recognition of the fact that consent is an ongoing process rather than a one-time agreement. Please do not hesitate to contact us if you have any questions regarding this information.

- **a.** You are participating in a research study that focuses on what happens to men after a cancer diagnosis. Participation involves the completion of this questionnaire.
- **b.** Your participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to which you are otherwise entitled.
- **c.** There is a small risk of breach of confidentiality; however we have taken many steps to minimize this risk, and in the 38 years of the study have never had a breach.
- **d.** Samples are sometimes shared with entities outside of Harvard as part of research collaborations; in such cases we use a separate ID number to ensure confidentiality.
- **e.** You will not receive monetary compensation for participating.
- **f.** There are no direct benefits to you from study participation.
- g. If you wish to speak with someone not directly involved in this research study about your rights as a research participant, please contact the Harvard TH Chan School of Public Health's Office for Human Research Administration at 617-432-2143 (local calls) or 866-606-0573 (long distance calls), or at: ohra@hsph.harvard.edu.
- **h.** If you have any questions regarding the study itself, please call the study Research Assistant at 617-435-0185.

THANK YOU FOR PREVIOUSLY PROVIDING VALUABLE INFORMATION RELATED TO YOUR PROSTATE CANCER. PLEASE NOTE THAT WE HAVE ALL OF YOUR ORIGINAL DIAGNOSIS INFORMATION. WE NOW SEEK TO LIBRATE YOUR INFORMATION.

O Yes – pl	ontinue to question 2 ease complete question	n 1a:					
. When did	d your PSA rise occ	cur?Year		What was y PSA value of			
	ever been diagno	sed with pro	ostate canc	er metastase	es to lymph	nodes,	
O Yes	other organs?	nue to questio	.n. 2				
Tes	O NO - Conti	nue to questio	111 3				
If yes:	Found <i>at</i> initial pro Found <i>after</i> prosta		_			FOR OFFIC	CE USE ONL
. At which	site(s) were you fou	nd to have m	etastases? P	lease mark a	ll that apply.	1234	Before 2022
						5 6 7 8	
O Lymph	nodes		Date diag		_/	9 10 11 12	
O 5			5	Mon		1 2 3 4	
O Bone			Date diag	nosed: Mon	th Year	5 6 7 8 9 10 11 12	
Other o	rgans, specify:		Date diag		/	1 2 3 4	
Other o	rgans, specify.		Date diag	Mon	th Year	5 6 7 8	
						9 10 11 12	2024 202
No No	Yes If yes, vote of your siblings or of that apply)	what date? _	Month Yea	ır			
(Mark all		_					
(Mark all	Prostate Cancer	Lung Cancer	Colon or Rectal Cancer	Melanoma	Breast Cancer	Pancreatic Cancer	Lymphon
Sister(s)	Cancer N/A	Cancer	Rectal Cancer	Melanoma		Cancer	0
Sister(s) Brother(s)	Cancer N/A	Cancer	Rectal Cancer	0	Cancer	Cancer	0
Sister(s)	Cancer N/A	Cancer	Rectal Cancer	0	Cancer	Cancer	

21.	For each question, please mark the <u>one</u> answer that comes closest to the way you have been feeling.	Not at All	A Little	Quite a Bit	Very Much	(2
	Do you have any trouble doing strenuous activities like carrying heavy shopping bags or a suitcase?	0	0	0	0	(
	Do you have any trouble taking a long walk?	0	0	0	\circ	(
	Do you have any trouble taking a short walk outside the house?	0	0	0	0	(
	Do you need to stay in bed or a chair during the day?	0	0	0	0	(
	Do you need help with eating, dressing, washing yourself or using the toilet?	0	0	0	0	(
22.	During the past week:	Not at All	A Little	Quite a Bit	Very Much	(2
	Were you limited in doing either your work or other daily activities?	0	0	0	0	(
	Were you limited in pursuing your hobbies or other leisure activities?	0	0	0	0	(
	Were you short of breath?	0	0	0	0	(
	Have you had pain?	0	0	0	0	(
	Have you had bone pain?	0	0	0	0	(
	Did you need rest?	0	0	0	\circ	(
	Have you had trouble sleeping?	0	0	0	0	(
	Have you felt weak?	0	0	0	0	(
	Have you lacked appetite?	0	0	0	0	(
	Have you felt nauseated?	0	0	0	\circ	(
	Have you vomited?	0	0	0	0	(
	Have you been constipated?	0	0	0	0	(
	Have you had diarrhea?	0	0	0	0	(
	Were you tired?	0	0	0	0	(
	Did pain interfere with your daily activities?	0	0	0	0	(
	Have you had difficulty in concentrating on things, like reading a newspaper or watching television?	0	0	0	0	(
	Did you feel tense?	0	0	0	0	(
	Did you worry?	0	0	0	0	(
	Did you feel irritable?	0	0	0	0	(
	Did you feel depressed?	0	0	0	0	(

PLEASE TURN PAGE OVER

ostate Cancer Survivors Biennial 2024	6		Health Pr	ofessionals Follow-Up Stu
20. House your seem had seem to see the	fan warm	.to oomeo?		
30. Have you <u>ever</u> had any treatment O No O Yes O Active Surveilla				
31. Since January 2022, have you had medications for your prostate can		t or		FOR OFFICE USE ONLY Treatment Code:
No Yes – please fill out the foll				1 2 3 4 5 6 7 8 9
	owing table (ora)			10 11 12 13 14 15 16 17 1
31a. Please mark all of the treatments	that you have	had since lar	mary 2022	19 20 21 22 23 24 25 26 2
31a. Thease mark an of the treatments	-		<u>lual y 2022</u> .	28 29 30 31 32
	Dates of Trea		currently	Start year:
	Start	End	doing/taking?	
				2022
Procedures	Year	Year		End year:
Radical prostatectomy		N/A		2022 2023
2. Radiation to the pelvis (external beam,		14,71	0	2024 2025
proton beam, cyberknife, etc.)				Treatment Code:
3. O Brachytherapy/seeds		N/A	0	12345678
4. Cryosurgery/cryoablation		N/A	0	10 11 12 13 14 15 16 17 (
5. High intensity focused ultrasound (HIFU)		N/A	0	19 20 21 22 23 24 25 26 2
Oral medications	Year	Year		28 29 30 31 32
				Start year:
6. Casodex (bicalutamide), Eulexin (flutamide)7. Estrogens and DES)		\bigcirc	Before 2022
8. Nilandron (nilutamide)			0	2022
9. Zytiga (abiraterone)			0	2024 () 2025 End year:
10. Xtandi (enzalutamide)	 			2022 2023
11.	+			2024 2025
12. C Erleada (apalutamide)			Ŏ	Treatment Code:
13. Nubeqa (darolutamide)			Ö	12345678
14. Rubraca (rucaparib)			0	10 11 12 13 14 15 16 17 (
15. O Zejula (niraparib)			0	19 20 21 22 23 24 25 26 2
6. Talzenna (talazoparib)			0	28 29 30 31 32
7. Orgovyx (relugolix)			0	Start year:
Injections/implants/infusions	Year	Year		Before 2022
8.				2022 2023 2024 2025
9. O Zoladex (goserelin)	 		0	End year:
20. Trelstar (triptorelin)			Ö	2022 2023
21. Plenaxis (abarelix)			Ŏ	2024 2025
22. Firmagon (degarelix)			Ö	Treatment Code:
23. Vantas (histrelin)			0	12345678
24. Zometa (zoledronic acid)			0	10 11 12 13 14 15 16 17 (
25. Xgeva (denosumab)			0	19 20 21 22 23 24 25 26 2
26. Jevtana (cabazitaxel)			0	28 29 30 31 32
27.			\bigcirc	Start year:
28. Provenge (sipuleucel-1) 29. Xofigo (Radium-223)			\bigcirc	Before 2022 2022 2023
30. O Pluvicto (¹¹²²Lu-PSMA-617)	+		0	2022 2023
31. (Keytruda (pembrolizumab)				End year:
32. OTHER, specify:	_			2022 2023
				2024 2025
	P	lease return f	orm to:	2222222
Thank you for your participation		H, 665 Huntir		4 4 4 4 4 4 4
you for your participation		Roston MA	•	8 8 8 8 8 8